omniture
雅创医药技术(上海)有限公司 HEPAGENE

Latest News

Hepagene Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for HPG7233 THR Beta Agonist

HONG KONG and NANJING, China, Sept. 20, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc. a clinical...

2023-09-20 22:00 1259

Hepagene Therapeutics to Present at the European Association for the Study of the Liver (EASL) Congress 2023

SHANGHAI, May 25, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc., a clinical stage biopharmaceuti...

2023-05-25 22:00 1880

Hepagene Therapeutics Reports Positive Top-line Results for Phase 2a RISE Study of FXR Agonist HPG1860 in Patients with NASH

SHANGHAI, Jan. 19, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc. a clinical stage biopharmaceut...

2023-01-19 23:00 2221

Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH

SHANGHAI, Dec. 2, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc, a clinical stage biopharmaceutic...

2021-12-02 23:00 1379

Hepagene Therapeutics, Inc. Announces Positive Results from Phase I Trial of HPG1860

SHANGHAI, Aug. 23, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc., a clinical stage biopharmaceut...

2021-08-23 22:00 1230

Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH

SHANGHAI, Oct. 16, 2019 /PRNewswire/ -- Hepagene Therapeutics, Inc, a clinical stage drug discovery...

2019-10-16 18:00 820